BPC 157 Ligament: 1 Unsafe Truth FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law BPC 157 for athletes and injury treatment: Science, safety, and legal concerns RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion